|Bid||3.63 x 800|
|Ask||3.64 x 1800|
|Day's Range||3.6300 - 3.6700|
|52 Week Range||1.7000 - 4.1400|
|Beta (3Y Monthly)||-1.06|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.20|
Avadel Pharmaceuticals plc (AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced that Kevin Kotler, the founder and Portfolio Manager of Broadfin Capital, LLC, has been appointed to the Company’s Board of Directors and will immediately join the Board. The Company also intends to nominate and appoint an additional director, in consultation with Broadfin, in the very near future.
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
BioDelivery (BDSI) delivered earnings and revenue surprises of 28.57% and -0.38%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Raleigh, North Carolina-based company said it had a loss of 29 cents per share. Losses, adjusted for non-recurring costs, came to 10 cents per share. The results topped Wall Street expectations. The ...
BELBUCA® continued on an accelerated growth trajectory, with revenue increasing 92% YOY and 27% versus prior quarterBELBUCA total prescriptions experienced its largest quarter.
The number of public companies based in the Triangle has shrunk in recent years as acquisitions have meant a change in headquarters location, or even taking the company private.
More than 100 million Covered Lives Now Have Preferred Access to BELBUCA RALEIGH, N.C., Nov. 01, 2018 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly.
BioDelivery (BDSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penny stocks got battered and bruised during the month of October, undermined by a broad-based retreat that dropped the Russell 2000 small-cap index to an eight-month low. The broad market could post new lows in early November, but a profitable relief rally should unfold in coming weeks, favoring dip trades on penny stocks that have held technical support levels through the maelstrom. This month's penny stock list includes several of these plays, but it's important to think and act defensively, placing stop losses immediately after entry. Penny Stock Picks to Buy Using Technical Analysis for November 1.
James Vollins joins the Company in role of General Counsel, Chief Compliance Officer, and Corporate Secretary Ernest De Paolantonio, Chief Financial Officer announces plan to.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Investors certainly have to be happy with BioDelivery Sciences International, Inc. (BDSI) and its short term performance.
From Iqvia to Red Hat to Bandwidth, insiders at Triangle companies continued to rake in millions in the third quarter by selling shares, U.S. Securities and Exchange Commission filings show.
The big shareholder groups in BioDelivery Sciences International Inc (NASDAQ:BDSI) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning Read More...
RALEIGH, N.C., Sept. 13, 2018-- BioDelivery Sciences International, Inc., a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced ...